Müller / Petry Lipases and Phospholipases in Drug Development

From Biochemistry to Molecular Pharmacology
1. Auflage 2006
ISBN: 978-3-527-60570-5
Verlag: Wiley-VCH
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 336 Seiten, E-Book

Dieses interdisziplinär angelegte Handbuch zu Lipasen und Phospholipasen wendet sich an Pharmazeuten, Biochemiker und Physiologen aus der Wirkstoffforschung. Untersucht werden zunächst die Grundlagen der Funktion von Lipasen in vitro und in vivo, anschließend die physiologische Rolle der Lipasen im normalen und im gestörten Stoffwechsel sowie die Entwicklung von Therapiekonzepten für Diabetes, Übergewicht und ähnliche Erkrankungen, die an Lipasen ansetzen. Besprochen wird außerdem der Einsatz von Phospholipasen für den Wirkstofftransport mithilfe von Liposomen und als diagnostische Hilfsmittel.

Autoren/Hrsg.

Müller, Günter

Petry, Stefan

Inhaltsverzeichnis

Purification of Lipase
Phospholipase A1: Structures, Physiological and Pathophysiological Roles in Mammals
Rational Design of a Liposomal Drug Delivery System Based on Biophysical Studies of Phospholipase A2 Activity
Phospholipase D
Sphingomyelinases and their Interaction with Membrane Lipids
Glycosyl-Phosphatidylinositol Cleavage Products in Signal Transduction
HTS of Hormone-sensitive Lipase and Subsequent Computer-assisted Compound Optimization
Endothelial Lipase: a Novel Drug Target for HDL and Atherosclerosis?
Digestive Lipases Inhibition: an in vitro Study.
Physiology of Gastrointestinal Lipolysis and Therapeutical Use of Lipases and Digestive Lipase Inhibitors
Physiological and Pharmacological Regulation of Triacylglycerol Storage and Mobilization

Über Autor(innen)

Günter Müller is senior scientist for Biochemistry at Aventis Pharma Germany, Frankfurt am Main, and honorary lecturer for genetics at the University of Munich. He was born in Peissenberg (Germany) and studied anthropology, zoology, genetics and biochemistry at the Ludwig-Maximilians-University in Munich, finishing his PhD thesis under the supervision of R. Zimmermann in 1987. After post-doctoral fellowships at the universities of Ulm and Heidelberg, he joined the pharmaceutical industry in 1990 and received his habilitation at the University of Munich in 1996. He is interested in molecular mechanisms in both lower eukaryotes and mammalian cells, and their use as drug targets for metabolic disorders.
******
Stefan Petry is senior scientist in Medicinal Chemistry at Aventis Germany, Frankfurt am Main. He was born in Kaiserslautern (Germany) and studied Chemistry and Biochemistry at the Albert-Ludwigs-University in Freiburg, including his PhD thesis under the supervision of Jochen Lehmann on photo-affinity labeling of carbohydrate binding proteins. He joined the pharmaceutical industry in 1994. At Aventis he is responsible for projects in the field of diabetes. In particular, he is interested in the development of small molecules which interact with signal transduction processes or influence lipid metabolism.